Novartis passes Phase III test for rare-disorder drug

Novartis ($NVS) has met the main goal of a late-stage study of the company's experimental drug against a rare endocrine disorder. The Swiss drug giant says its experimental drug pasireotide LAR b…
Read the full story: News